Neuland Laboratories Reports Mixed Q2FY27 Results Amid Robust H1 Growth
Neuland Laboratories Ltd · Investor Presentation · 03 Nov 2026, 9:54 pm
Neuland Laboratories Reports Mixed Q2FY27 Results Amid Robust H1 Growth Neuland Laboratories reported standalone total income of ₹457.2 Cr for Q2FY27, down 11.4% YoY. EBITDA declined 33.4% YoY to ₹104.6 Cr, with margins contracting 754 bps YoY to 22.9% due to operating deleverage. PAT fell 47.0% YoY to ₹51.1 Cr, while diluted EPS stood at ₹39.9. Conversely, H1FY27 total income grew 35.6% YoY to ₹1,107.2 Cr, and PAT rose 80.2% YoY to ₹198.5 Cr. Net cash stood at ₹208.0 Cr. Active CMS projects reached 99, supported by ongoing capex in peptides and R&D.
Original exchange filing (PDF)
More announcements from Neuland Laboratories Ltd
- Intimation about Schedule of Analyst / Institutional Investor Meeting on November 17, 2026 · 06 Nov 2026
- Change in Corporate Office Address of Registrar and Share Transfer Agent (RTA) · 05 Nov 2026
- Audio Recording of the Earnings call conducted on November 3, 2026 · 04 Nov 2026
- Press Release on the Financial Results of the Company for the quarter and half year ended September 30, 2026 · 03 Nov 2026
- Disclosure under Regulation 30 of SEBI Listing Regulations · 03 Nov 2026
- Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 · 03 Nov 2026
- Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 03 Nov 2026
- Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 · 03 Nov 2026
